慢性閉塞性肺疾患(COPD)治療薬の世界市場2016-2020

◆英語タイトル:Global Chronic Obstructive Pulmonary Disease Drugs Market 2016-2020
◆商品コード:IRTNTR9968
◆発行会社(調査会社):Technavio
◆発行日:2016年7月20日
◆ページ数:107
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、慢性閉塞性肺疾患(COPD)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、慢性閉塞性肺疾患(COPD)治療薬の世界市場規模及び予測、技術別分析、製品別分析、薬剤種類別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Chronic Obstructive Pulmonary Disease (COPD)
COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing.

Technavio’s analysts forecast the global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Teva

[Other prominent vendors]
• Ache Laboratorios Farmaceuticos
• Almirall
• Aquinox Pharmaceuticals
• Ario Pharma
• Asmacure
• Astellas Pharma
• BioMarck Pharmaceuticals
• Chiesi Farmaceutici
• Cytokinetics
• F. Hoffmann-La Roche
• Gilead Sciences
• Innoviva
• Invion
• MediciNova
• Mereo BioPharma
• Mylan
• Orion Corporation
• Palobiofarma
• Pearl Therapeutics
• Pharmaxis
• Prosonix
• Pulmagen Therapeutics
• RespiVert
• SolAeroMed
• Sunovion Pharmaceuticals
• Theravance Biopharma
• Theron Pharmaceuticals
• Verona Pharma
• Xention
• Yungjin Pharm
• ZAI Lab

[Market driver]
• Uptake of LABA/LAMA combination therapies
• For a full, detailed list, view our report

[Market challenge]
• Negligence toward use of controller medications
• For a full, detailed list, view our report

[Market trend]
• Increased adoption of e-cigarettes and smoking cessation products
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Breakthrough in COPD research
• COPD: An overview

PART 05: Pipeline analysis

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Key buying criteria for COPD drugs

PART 08: Market segmentation by drug class
• Combination therapies
• Bronchodilators
• Steroids
• Leukotriene antagonists
• PDE-4 inhibitors
• Other medications

PART 09: Segmentation by ROA
• Inhalation
• Oral

PART 10: Drug delivery devices market for COPD drugs
• Market overview
• Market segmentation by product type

PART 11: Geographical segmentation
• Global COPD drugs market by geography 2015-2020
• COPD drugs market in Americas
• COPD drugs market in EMEA
• COPD drugs market in APAC
• COPD drugs market in China

PART 12: Market drivers
• Increase in smoking prevalence
• Uptake of LABA/LAMA combination therapies
• Robust pipeline with tentative approval of drugs

PART 13: Impact of drivers

PART 14: Market challenges
• Lack of innovation in pipeline molecules
• Negligence toward use of controller medications
• Low diagnosis rates

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Innovative technologies for drug delivery
• Increased adoption of e-cigarettes and smoking cessation products
• Emergence of ultrasonic nebulizers
• Increase in online marketing services
• Growing use of home healthcare devices

PART 17: Vendor landscape
• Competitive scenario
• Key news

PART 18: Key vendor analysis
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Novartis
• Teva Pharmaceuticals
• Other prominent vendors

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Breakthrough research activities in field of COPD
Exhibit 03: Percentage share of pipeline molecules based on stage of development
Exhibit 04: Pipeline molecules based on MOA and stage of development
Exhibit 05: Percentage share of pipeline drugs based on MOA
Exhibit 06: Global COPD drugs market 2015-2020 ($ billions)
Exhibit 07: Global COPD drugs market snapshot: Developed and emerging markets 2015
Exhibit 08: Global COPD drugs market: Key parameters driving the market 2015
Exhibit 09: Five forces analysis
Exhibit 10: Key buying criteria for COPD drugs
Exhibit 11: Impact of key customer segments on global COPD drugs market
Exhibit 12: Segmentation of COPD drugs based on drug class
Exhibit 13: Percentage share of global COPD drugs by drug class based on revenue 2015
Exhibit 14: Global COPD drugs market: Drug class segmentation growth cycle analysis 2015
Exhibit 15: Combination therapies market in global COPD drugs market 2015-2020 ($ billions)
Exhibit 16: Bronchodilators market in global COPD drugs market 2015-2020 ($ billions)
Exhibit 17: Steroid drugs market in global COPD drugs market 2015-2020 ($ billions)
Exhibit 18: Leukotriene antagonists market in global COPD drugs market 2015-2020 ($ billions)
Exhibit 19: YoY growth and revenue of Daliresp 2012-2015 ($ billions)
Exhibit 20: Global COPD drugs market segmentation by drug class 2015
Exhibit 21: Segmentation of global COPD drugs market by ROA
Exhibit 22: Global COPD drug delivery devices market 2015-2020 ($ millions)
Exhibit 23: Global COPD devices market segmentation by product type
Exhibit 24: Percentage share of global COPD drug delivery devices by type 2015
Exhibit 25: Percentage share of inhalers in global COPD drug delivery devices market 2015
Exhibit 26: Inhalers market in global COPD drug-devices market 2015-2020 ($ millions)
Exhibit 27: Percentage share of nebulizers in global COPD drug delivery devices market by technology 2015
Exhibit 28: Nebulizers market in global COPD drug-devices market 2015-2020 ($ millions)
Exhibit 29: Global COPD drugs market by geography 2015-2020
Exhibit 30: Percentage share of global COPD drugs market by geography 2015 and 2020
Exhibit 31: Global COPD drugs market segmentation by geography 2015-2020 ($ billions)
Exhibit 32: Global share of COPD drugs market by geography 2015
Exhibit 33: COPD drugs market in Americas 2015-2020 ($ billions)
Exhibit 34: Prevalence rates of COPD in few countries of EMEA
Exhibit 35: COPD drugs market in EMEA 2015-2020 ($ billions)
Exhibit 36: COPD drugs market in APAC 2015-2020 ($ billions)
Exhibit 37: COPD drugs market in China 2015-2020 ($ billions)
Exhibit 38: Global COPD drugs market: Country analysis based on revenue and growth rate
Exhibit 39: Drug approvals in COPD drugs market in past three years (2014-2016)
Exhibit 40: Few COPD drug molecules in registration stage
Exhibit 41: Impact of drivers
Exhibit 42: Controller and rescue medications for the treatment of COPD
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Key vendors ranking 2015
Exhibit 45: Market share of key vendors based on revenues 2015
Exhibit 46: Geographical presence of key vendors
Exhibit 47: Competitive scenario of global COPD drugs market vendors 2015-2020
Exhibit 48: AstraZeneca: YoY revenue and growth rate of Symbicort 2013-2015 ($ billions)
Exhibit 49: AstraZeneca: Geographical segmentation of Symbicort 2015
Exhibit 50: AstraZeneca: YoY revenue and growth rate of Pulmicort 2013-2015 ($ millions)
Exhibit 51: AstraZeneca: Geographical segmentation of Pulmicort 2015
Exhibit 52: AstraZeneca: Metrics analysis
Exhibit 53: Boehringer Ingelheim: YoY revenue and growth rate of Spiriva 2013-2015 ($ billions)
Exhibit 54: Boehringer Ingelheim: Metrics analysis
Exhibit 55: GSK: YoY revenue and growth rate of Seretide/Advair 2013-2015 ($ billions)
Exhibit 56: Geographical segmentation of Seretide/Advair 2015
Exhibit 57: GSK: YoY revenue and growth rate of Flixotide/Flovent 2013-2015 ($ billions)
Exhibit 58: GSK: Geographical segmentation of Flixotide/Flovent 2015
Exhibit 59: GSK: YoY revenue and growth rate of Ventolin 2013-2015 ($ billions)
Exhibit 60: GSK: Geographical segmentation of Ventolin 2015
Exhibit 61: GSK: YoY growth and revenue of Relvar/Breo Ellipta 2014-2015 ($ millions)
Exhibit 62: GSK: Geographical segmentation of Relvar/Breo Ellipta 2015
Exhibit 63: GSK: YoY growth and revenue of Anoro Ellipta 2014-2015 ($ millions)
Exhibit 64: GSK: Geographical segmentation of Anoro Ellipta 2015
Exhibit 65: GSK: Metrics analysis
Exhibit 66: Novartis: YoY revenue and growth rate of Onbrez Breezhaler/Arcapta Neohaler 2014-2015 ($ millions)
Exhibit 67: Novartis: YoY revenue and growth rate of Seebri Breezhaler 2013-2015 ($ millions)
Exhibit 68: Novartis: YoY revenue and growth rate of Ultibro Breezhaler 2013-2015 ($ millions)
Exhibit 69: Novartis: Metrics analysis
Exhibit 70: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)
Exhibit 71: Teva Pharmaceuticals: YoY revenue and growth rate of Qvar 2013-2015 ($ millions)
Exhibit 72: Teva Pharmaceuticals: Metrics analysis



【掲載企業】

AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals, Chiesi Farmaceutici, Cytokinetics, F. Hoffmann-La Roche, Gilead Sciences, Innoviva, Invion, MediciNova, Mereo BioPharma, Mylan, Orion Corporation, Palobiofarma, Pearl Therapeutics, Pharmaxis, Prosonix, Pulmagen Therapeutics, RespiVert, SolAeroMed, Sunovion Pharmaceuticals, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention , Yungjin Pharm, ZAI Lab.

【レポートのキーワード】

慢性閉塞性肺疾患(COPD)、COPD薬、治療、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[慢性閉塞性肺疾患(COPD)治療薬の世界市場2016-2020]販売に関する免責事項
★調査レポート[慢性閉塞性肺疾患(COPD)治療薬の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆